Close Menu
Home » Scipher Medicine Builds Evidence for Tests Predicting Response to Autoimmune Disease Drugs

Scipher Medicine Builds Evidence for Tests Predicting Response to Autoimmune Disease Drugs

Jan 09, 2019
|
Molika Ashford
Premium

NEW YORK (GenomeWeb) – Scipher Medicine of Boston is hoping to develop molecular signatures that can predict a patient's response to autoimmune disease drugs, pushing precision medicine into areas other than oncology.

The company, which was founded in 2014 by researchers at Northeastern University, Harvard, and Brigham and Women's Hospital, uses a proprietary approach for discovering RNA signatures, which it is applying first to predict response to anti-TNF drugs in rheumatoid arthritis and ulcerative colitis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Hundreds and Hundreds Retracted

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

Guilty Plea in Kickback Case

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

Florida Bill Moves Ahead

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

Science Presents Studies Into Disease-Causing Mutations Among Bone Marrow Donors; Links Between Heavy Drinking, Other Disease

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Featured Webinar

Development of a Novel Multiplex Assay: A Partnership Case Study

Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

Feb
20
Featured Webinar

Advances in NGS Gene Expression Studies to Reduce The Cost of Sequencing

Sponsored by
Thermo Fisher Scientific

This webinar will discuss the use of 3’ mRNA sequencing to reduce the cost of gene expression studies on Illumina NGS systems.

Feb
26
Featured Webinar

Transformation of the Lab to Fight Genetic Illnesses in the Amish and Mennonite Populations

Sponsored by
Autogen

This webinar will explain how the Clinic for Special Children in Strasburg, Pennsylvania, has transformed its DNA workflows to improve the diagnosis and treatment of genetic illnesses that are prevalent in the pediatric population of its community.

What's Popular?

In Molecular Diagnostics

  1. JP Morgan Healthcare Day 2: 10x Genomics, GenapSys, Caris, Adaptive Bio, Danaher, Agilent, Luminex

  2. JP Morgan Healthcare Day 3: Exact Sciences, NanoString, Natera, Horizon, Accelerate Dx, GenMark, More

  3. JP Morgan Healthcare Day One: Qiagen, Guardant Health, Bio-Rad, Hologic, Myriad Genetics

  4. Color Raises $75M to Scale Infrastructure

  5. Roche, Illumina Partner on Next-Generation Sequencing IVD, CDx Development, Marketing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.